secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001104659-24-067483
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports positive Phase 2a data for obesity drug GSBR-1290
--------------------------------------------------------------------------------

- GSBR-1290 achieved placebo-adjusted mean weight loss of 6.2% (p<0.0001) in Phase 2a obesity study at 12 weeks.
- Capsule to tablet PK study showed up to 6.9% placebo-adjusted weight loss (p<0.0001) with new tablet formulation.
- 67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% ≥10% loss vs 0% for placebo.
- Adverse events were GI-related; discontinuations 5% in Phase 2a and 11% in PK study; no liver injury.
- Phase 2b obesity study expected to begin Q4 2024 with ~300 participants using tablet formulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924067483/0001104659-24-067483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924067483/tm2414821d7_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-067483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer